Vertex Pharmaceuticals develops biotechnology medicines for serious diseases and conditions, with commercial franchises in cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain. Company news commonly covers CFTR modulators including ALYFTREK and TRIKAFTA, the CRISPR/Cas9 gene-edited therapy CASGEVY, and JOURNAVX, an oral non-opioid pain signal inhibitor.
Updates also track financial results, regulatory approvals and label expansions, reimbursement and patient-access agreements, clinical data presentations, and pipeline programs in kidney disease, neuropathic pain, type 1 diabetes, generalized myasthenia gravis and myotonic dystrophy type 1. Vertex disclosures frequently connect revenue trends with progress across approved products and investigational programs such as povetacicept for IgA nephropathy.
Vertex Pharmaceuticals (VRTX) published Phase 3 RAINIER results showing povetacicept met its primary and both secondary endpoints in IgA nephropathy. The pre-specified Week 36 interim analysis showed a 52.0% reduction from baseline in proteinuria, or protein in urine, and a 49.8% reduction versus placebo (P<0.0001). Results appeared in the New England Journal of Medicine and were presented at ASN Kidney Week 2026.
The secondary endpoints measured a disease-related antibody and resolution of blood in urine. No serious adverse events related to povetacicept or deaths occurred, although some adverse events were more frequent than with placebo. The FDA accepted the application for accelerated approval, with a November 30, 2026 target action date. RAINIER remains blinded through 104 weeks; its final primary endpoint measures kidney-function decline. A Phase 3b autoinjector patient-experience study is also underway.
Vertex Pharmaceuticals (VRTX) has appointed Daniel Brennan, a former Boston Scientific chief financial officer, to its board as an independent director. Brennan has more than 35 years of experience in healthcare finance, including more than 25 years at Boston Scientific, where he retired last year as executive vice president and chief financial officer. With his appointment, Vertex increased its board from 10 to 11 members.
Vertex Pharmaceuticals (VRTX) presented interim ALYFTREK data showing recovery of pancreatic function in some children with cystic fibrosis aged 2 to 5.
The ongoing open-label extension study assessed children after at least 48 weeks of treatment. Mean fecal elastase-1, a measure of pancreatic function, was 239.7 μg/g, up 110.2 μg/g from baseline; 48.6% reached the pancreatic sufficiency threshold of ≥200 μg/g. Of 48 children eligible for a substudy, 18 (37.5%) successfully stopped pancreatic enzyme replacement therapy (PERT), for a mean 8.6 weeks at the interim analysis. Another 7 participants had stopped PERT before substudy eligibility. Across the full cohort of 66 children, 50% were not receiving PERT at the data cut.
The findings were presented at the North American Cystic Fibrosis Conference. ALYFTREK use in children aged 2 to 5 remains investigational.
Vertex Pharmaceuticals (Nasdaq: VRTX) will report third quarter 2026 financial results on November 2, 2026, after financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast will be accessible through the Investors section of Vertex's website, where an archived webcast will also be available.
Vertex (VRTX) reported positive Phase 2b AMPLIFIED results for inaxaplin in APOL1-mediated kidney disease and completed AMPLITUDE enrollment.
In AMKD patients with modest proteinuria (cohort 1), once-daily 45 mg inaxaplin on top of optimized standard of care reduced urine albumin-to-creatinine ratio (UACR) by 42.7% and urine protein-to-creatinine ratio (UPCR) by 44.7% at Week 13 versus baseline. In AMKD patients with type 2 diabetes (cohort 2), UACR fell 17.3% and UPCR 25.4%, with 95% confidence intervals for both cohorts reported post hoc.
Across 41 treated participants, inaxaplin was generally safe and well tolerated, with no inaxaplin-related serious adverse events and mostly mild or moderate adverse events. Enrollment is now complete in the global Phase 2/3 AMPLITUDE trial in severe proteinuria AMKD, with a pre-planned 48-week interim analysis expected in early 2027 that could, if positive, support potential U.S. accelerated approval.
Vertex (VRTX) has partnered with world champion skier Lindsey Vonn to raise awareness of JOURNAVX (suzetrigine), an FDA‑approved, first‑in‑class, oral non‑opioid medicine for the treatment of moderate‑to‑severe acute pain in adults. JOURNAVX was approved in the U.S. on January 30, 2025, and has since been prescribed to over one million Americans.
Vonn is sharing her experience using JOURNAVX to manage acute postoperative pain following multiple surgeries after a 2026 Winter Games injury. JOURNAVX selectively inhibits the NaV1.8 sodium channel in peripheral pain‑sensing neurons, aiming to block pain signals outside the brain and avoid limitations of some existing therapies, including the addictive potential of opioids. The safety information highlights contraindication with strong CYP3A inhibitors, need for dosage adjustments with moderate CYP3A inhibitors and certain CYP3A substrates, precautions with some hormonal contraceptives, avoidance in severe hepatic impairment, and common adverse reactions such as pruritus, muscle spasms, increased creatine phosphokinase, and rash.
Vertex (Nasdaq: VRTX) completed its acquisition of Crinetics Pharmaceuticals (Nasdaq: CRNX) on September 1, 2026, under a previously announced definitive agreement valuing Crinetics at approximately $10.0 billion, or about $8.8 billion net of estimated cash acquired. According to Vertex, the deal adds PALSONIFY (paltusotine), the first once-daily oral therapy for acromegaly, and atumelnant, an oral ACTH receptor antagonist in Phase 3 for congenital adrenal hyperplasia and Phase 2 for Cushing’s syndrome, plus additional endocrine programs.
Vertex said PALSONIFY and atumelnant together have potential to generate more than $5 billion in peak annual revenue and expects the transaction to become accretive to non-GAAP operating income in 2029. The acquisition establishes rare endocrine diseases as a new growth pillar. Vertex also expanded its leadership team: Charles Wagner will oversee Crinetics integration as EVP, COO; Jonathan Poole will become EVP, CFO effective January 1, 2027; and Jasper van Grunsven will join on September 8, 2026 as EVP, Chief Pain and New Product Planning Officer.
Vertex (Nasdaq: VRTX) announced that its management team will participate in four investor conferences in September 2026, including events hosted by Wells Fargo, Cantor, Morgan Stanley and Bank of America in Boston, New York and London. The sessions will feature fireside chats with senior investor relations leaders and the CEO. Live webcasts and archived replays will be available on Vertex’s website in the Investors > News and Events section.
Crinetics Pharmaceuticals (Nasdaq: CRNX) reported second-quarter 2026 revenue of $25.1 million, up from $1.0 million a year earlier, including $24.0 million in PALSONIFY net product revenue following its U.S. launch. Net loss was $120.9 million, or $1.14 per share. Cash, cash equivalents and investment securities totaled $1.2 billion at June 30, 2026.
On July 6, 2026, Vertex Pharmaceuticals (Nasdaq: VRTX) and Crinetics entered a definitive agreement for Vertex to acquire Crinetics for $85.00 per share in cash, implying total equity value of about $10.0 billion, or $8.8 billion net of estimated cash acquired. The transaction was unanimously approved by both boards and is expected to close in the third quarter of 2026, subject to regulatory and Crinetics stockholder approvals. Crinetics also received FDA Rare Pediatric Disease Designation for Phase 3 candidate atumelnant in classic congenital adrenal hyperplasia and withdrew financial guidance due to the pending transaction.
Vertex (Nasdaq: VRTX) reported second quarter 2026 total revenue of $3.33 billion, up 12% year over year, driven by cystic fibrosis therapies, CASGEVY, and JOURNAVX. U.S. revenue was $2.06 billion (+11%), and revenue outside the U.S. was $1.28 billion (+14%).
Combined GAAP and non-GAAP R&D, acquired IPR&D and SG&A expenses were $1.6 billion and $1.4 billion, respectively, versus $1.4 billion and $1.2 billion a year ago. GAAP and non-GAAP net income were $1.1 billion and $1.2 billion. Cash and marketable securities rose to $13.6 billion.
Vertex raised 2026 total revenue guidance to $13.1–$13.2 billion, embedding at least $0.5 billion of non-CF product revenue, and reiterated expense guidance. The company agreed to acquire Crinetics Pharmaceuticals, expects closing in Q3 2026, and advanced its pipeline, including a povetacicept BLA for IgAN with a PDUFA date of November 30, 2026.